Daily Cardiology Research Analysis
Analyzed 171 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology papers stood out: a Circulation study uncovered an autoimmune axis in cardiac sarcoidosis, including a candidate autoantigen (periplakin). An individual patient data meta-analysis in European Heart Journal defined an optimal potassium range (4.2–5.0 mmol/L) for heart failure outcomes. A large JAMA network meta-analysis compared adverse effects and discontinuation across major antihypertensive classes, revealing ARB regimens as notably better tolerated.
Research Themes
- Autoimmune mechanisms and target discovery in inflammatory cardiomyopathies
- Electrolyte optimization thresholds in heart failure management
- Tolerability-driven selection of antihypertensive regimens to improve adherence
Selected Articles
1. Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis.
Single-cell and spatial transcriptomics of human cardiac sarcoidosis revealed region-specific inflammatory programs and an intracardiac humoral autoimmune axis. Clonally expanded B cells produced antibodies that recognized periplakin, a desmosomal protein, implicating autoantigen-driven mechanisms alongside inflammasome/pyroptosis signaling and tertiary lymphoid structures.
Impact: Identifying periplakin as a candidate autoantigen in cardiac sarcoidosis reframes the disease as a targeted autoimmune process and opens avenues for antigen-specific or B-cell–directed therapies.
Clinical Implications: Supports exploring B-cell/BAFF pathway inhibition, modulation of macrophage fusion programs, and potential antigen-specific tolerance strategies in cardiac sarcoidosis, alongside current immunosuppression.
Key Findings
- Granulomatous, fibrotic, and preserved myocardium regions showed distinct cellular programs; cardiomyocytes upregulated inflammasome and pyroptosis transcripts.
- Macrophages in granulomas expressed fusion modulators; Th17-skewed T cells upregulated BAFF, supporting B-cell activation.
- Fibrotic regions contained tertiary lymphoid structures with clonal B/plasma cell expansion.
- Reconstructed antibodies from cardiac B-cell clones bound periplakin and other cardiac cell peptides, not microbial/allergen peptides.
Methodological Strengths
- Integrated single-cell and spatial transcriptomics across histologically defined regions in human hearts.
- Reconstruction and functional epitope screening of antibodies from clonally expanded cardiac B cells.
Limitations
- Observational, tissue-based analyses limit causal inference and generalizability.
- Therapeutic implications require in vivo validation and clinical translation.
Future Directions: Validate periplakin and additional autoantigens across larger cohorts; test B-cell/BAFF-targeted and antigen-specific tolerance strategies in preclinical CS models; develop biomarkers predicting autoimmune activity and arrhythmogenic risk.
BACKGROUND: Cardiac sarcoidosis (CS) is an enigmatic disorder characterized by unexplained patchy, sterile granulomas intermixed with preserved myocardium and fibrotic regions without granuloma. CS causes arrhythmias, sudden cardiac death, and heart failure. The mechanisms producing this remarkable histopathology and disease progression remain unexplained. METHODS: Using comprehensive single-cell and spatial transcriptomic analyses, we characterized the cellular composition and gene expression in preserv
2. Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis.
Across 716 double-blind RCTs (159,362 participants; mean follow-up 8.6 weeks), ARB monotherapy and ARB+CCB had fewer discontinuations than placebo, while CCBs, ACEi+CCB, and β-blocker+thiazide increased discontinuations. All regimens increased dizziness; all except CCBs reduced headache. Several combinations were better tolerated than monotherapies, suggesting net symptomatic benefit.
Impact: Provides comparative tolerability rankings across antihypertensive classes/combos using randomized evidence, directly informing regimen selection to improve adherence and BP control.
Clinical Implications: Favor ARB-based regimens (especially ARB+CCB) when tolerability is paramount; anticipate class-specific symptoms (e.g., dizziness) and counsel patients. Short-term RCT data suggest some combinations may reduce withdrawals versus monotherapy.
Key Findings
- ARB monotherapy (OR 0.73, 95% CrI 0.61–0.86) and ARB+CCB (OR 0.61, 0.47–0.79) had fewer discontinuations than placebo.
- CCBs (OR 1.43, 1.23–1.67), ACEi+CCB (OR 1.46, 1.13–1.87), and β-blocker+thiazide (OR 1.58, 1.04–2.47) increased discontinuations versus placebo.
- All regimens increased dizziness; all but CCBs reduced headache; some combinations ranked better than placebo for discontinuation risk.
Methodological Strengths
- Large-scale fixed-effect network meta-analysis of double-blind RCTs with class-based synthesis.
- Standardized extraction by independent reviewers and Bayesian credible intervals with SUCRA ranking.
Limitations
- Short-term follow-up (4–26 weeks) may not reflect long-term tolerability or rare AEs.
- Trial-level network assumptions and heterogeneity may not apply to individual patients.
Future Directions: Head-to-head pragmatic trials and patient-level NMA assessing long-term tolerability and adherence; evaluate symptom burden and quality-of-life impacts across regimens.
IMPORTANCE: Adverse drug effects from blood pressure (BP)-lowering drugs contribute to significant undertreatment and poor overall BP control rates. OBJECTIVE: To review adverse effects and discontinuation of BP-lowering drugs and their combinations from the 5 major classes in short-term clinical trials. DATA SOURCES AND STUDY SELECTION: Cochrane Central Register of Controlled Trials for randomized clinical trials, MEDLINE, and Epistemonikos were searched from the date of inception until December 31, 2024, for double-blind randomized clinical trials of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers (ARBs), β-blockers, calcium channel blockers (CCBs), thiazide and thiazide-like diuretics, or their combinations, with follow-up durations between 4 and 26 weeks. DATA EXTRACTION AND SYNTHESIS: Data extraction was performed by 2 independent reviewers. Synthesis was performed using fixed-effect network meta-analyses according to drug class, summarized using odds ratios (ORs) and 95% credible intervals (CrIs) and surface under the cumulative ranking curves. Final statistical analysis was conducted in April 2026. MAIN OUTCOMES AND MEASURES: Treatment discontinuation due to adverse events (AEs), defined as discontinuation of randomized treatment due to an AE. Secondary outcomes included headache, dizziness, edema, and cough.
3. Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.
An IPD meta-analysis of 12 RCTs (n=46,069) found a reverse J-shaped (HFrEF) and flatter U-shaped (HFpEF) association between baseline potassium and adverse outcomes, with nadir risk at 4.2–5.0 mmol/L. Hypokalemia was strongly harmful; mild hyperkalemia (5.0–5.5 mmol/L) did not worsen outcomes in HFrEF.
Impact: Defines a practical potassium target range across HF phenotypes using randomized trial IPD, informing RAASi/MRA optimization and hyperkalemia risk management without compromising survival.
Clinical Implications: Aim for 4.2–5.0 mmol/L potassium in HF; aggressively avoid hypokalemia; do not reflexively de-escalate guideline therapies for mild hyperkalemia (5.0–5.5 mmol/L) without other risk signals.
Key Findings
- Reverse J-shaped (HFrEF) and flatter U-shaped (HFpEF) relations between potassium and outcomes; nadir risk at 4.2–5.0 mmol/L.
- Potassium <3.5 mmol/L linked to higher all-cause mortality (aHR 1.49, 95% CI 1.27–1.76) and CV/sudden/pump failure death in HFrEF.
- Mild hyperkalemia (5.0–5.5 mmol/L) was not associated with worse outcomes in HFrEF; similar optimal range observed in HFpEF.
Methodological Strengths
- Individual patient data meta-analysis across 12 randomized trials with phenotype-specific analyses.
- Robust modeling using categorical and spline-based continuous potassium analyses with multiple outcomes.
Limitations
- Baseline potassium used; time-updated trajectories and treatment changes not captured.
- Trial populations may not fully reflect advanced CKD or severe hyperkalemia settings.
Future Directions: Prospective studies testing potassium-guided titration of RAASi/MRA and potassium-binders; evaluate dynamic potassium monitoring strategies and hard outcomes across HF phenotypes.
BACKGROUND AND AIMS: It remains unclear what the safe serum potassium range is in heart failure (HF) and whether it is the same in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). METHODS: A patient-level pooled analysis from 12 randomized controlled trials including 32 346 HFrEF and 13 723 HFpEF patients was performed. Baseline serum potassium level was categorized into six groups (<3.5, ≥3.5-<4.0, ≥4.0-<4.5, ≥4.5-<5.0, ≥5.0-<5.5, and ≥5.5 mmol/L) and serum potassium level at baseline was also analysed as a continuous variable using restricted cubic splines. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, sudden death, pump failure death, first HF hospitalization, and composites of HF hospitalization and cardiovascular or all-cause death. RESULTS: The median follow-up was 24.2 and 36.8 months in HFrEF and HFpEF trials, respectively. In HFrEF, serum potassium levels showed a reverse J-shaped association with outcomes. Compared with ≥4.0-4.5 mmol/L (reference), potassium <3.5 mmol/L was associated with higher risks of all-cause mortality (adjusted hazard ratio 1.49; 95% confidence interval, 1.27-1.76), as well as cardiovascular, sudden, and pump failure death. The lowest risk for all outcomes was observed within the baseline serum potassium range of 4.2-5.0 mmol/L, but even 'mild hyperkalaemia' (5.0-5.5 mmol/L) was not associated with worse outcomes in HFrEF. Although the risk curve was U-shaped and flatter in HFpEF, the lowest incidence of all outcomes was observed over the same potassium range as HFrEF. CONCLUSION: In HFrEF, hypokalaemia is strongly associated with worse outcomes and should be avoided. In terms of safety, the optimal serum potassium concentration in both HFrEF and HFpEF appears to be in the range 4.2-5.0 mmol/L.